[{"id":"9c52b3ba-74cb-41b4-9ef2-03d1ced908cf","acronym":"IMGN151-1001","url":"https://clinicaltrials.gov/study/NCT05527184","created_at":"2024-02-01T02:20:14.331Z","updated_at":"2025-02-25T12:28:59.108Z","phase":"Phase 1","brief_title":"First in Human Study of IMGN151 in Recurrent Gynaecological Cancers","source_id_and_acronym":"NCT05527184 - IMGN151-1001","lead_sponsor":"AbbVie","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opugotamig olatansine (IMGN-151)"],"overall_status":"Recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"}]